Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b/3 study

被引：0
|
作者：
Goadsby, P. J. [1 ]
Dodick, D. W. [2 ]
Ailani, J. [3 ]
Trugman, J. M. [4 ]
Finnegan, M. [4 ]
Lakkis, H. [4 ]
Lu, K. [4 ]
Szegedi, A. [4 ]
机构：
[1] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[2] Mayo Clin, Phoenix, AZ USA
[3] Medstar Georgetown Univ Hosp, Washington, DC USA
[4] Allergan Plc, Madison, NJ USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO3117
引用
收藏
页码：811 / 811
页数：1
相关论文
共 50 条
  • [1] Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results from a Phase 2b/3 Study
    Goadsby, P. J.
    Dodick, D. W.
    Ailani, J.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Lu, K.
    Szegedi, A.
    HEADACHE, 2019, 59 : 18 - 19
  • [2] Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study
    Goadsby, Peter J.
    Dodick, David W.
    Ailani, Jessica
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Lu, Kaifeng
    Szegedi, Armin
    CEPHALALGIA, 2019, 39 : 182 - 183
  • [3] Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study
    Goadsby, Peter J.
    Dodick, David W.
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Lu, Kaifeng
    Szegedi, Armin
    NEUROLOGY, 2019, 92 (15)
  • [4] EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED ATOGEPANT FOR THE PREVENTION OF EPISODIC MIGRAINE: RESULTS FROM A PHASE 2B/3 STUDY
    Goadsby, P. J.
    Dodick, D. W.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Lu, K.
    Szegedi, A.
    CEPHALALGIA, 2018, 38 : 144 - 145
  • [5] Efficacy, Safety, and Tolerability of Orally Administered Atogepant for the Prevention of Episodic Migraine: Results from a Phase 2b/3 Study
    Goadsby, Peter J.
    Dodick, David W.
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Lu, Kaifeng
    Szegedi, Armin
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [6] Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial
    Goadsby, Peter J.
    Dodick, David W.
    Ailani, Jessica
    Trugman, Joel M.
    Finnegan, Michelle
    Lu, Kaifeng
    Szegedi, Armin
    LANCET NEUROLOGY, 2020, 19 (09): : 727 - 737
  • [7] Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial (vol 19, pg 727, 2020)
    Goadsby, P. J.
    Dodick, D. W.
    Ailani, J.
    LANCET NEUROLOGY, 2020, 19 (11): : E10 - E10
  • [8] Atogepant for the preventive treatment of chronic migraine: Results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Goadsby, P. J.
    HEADACHE, 2022, 62 (07): : 923 - 923
  • [9] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    Goadsby, P.
    Lipton, R.
    Reuter, U.
    Guo, H.
    Schwefel, B.
    Boinpally, R.
    McCusker, E.
    Yu, S. Yun
    Finnegan, M.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [10] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter J.
    Lipton, Richard
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Boinpally, Ramesh
    McCusker, Emily
    Yu, Sung Yun
    Finnegan, Michelle
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 14 - 15
12345